MCKESSON CORP

NYSE: MCK·Irving, Texas·

Price
$1,105.04
Base IV
$1,149.07

Valuation snapshot

Below base case

At $1,105.04, the price sits between our bear case ($764.42) and base case ($1,149.07).

Values per share, from an .

No growth
…
Loading earnings power
Base case
$1,149.07
above today's price · range $764.42–$1,684.78
Price vs base case
4% below
$1,105.04 against $1,149.07
Base casevalued by DCF
Price vs base
Priceclose 11‑16

The price has risen 3.1% since this valuation was struck on 2026-11-06, so some of the gap opened up after these figures were set.

Whisker on the base case runs bear $764.42 to bull $1,684.78. Values per share.

Price against each value

Bear case
$764.42
Price 45% above
No growth
…
—
Base case
$1,149.07
Price 4% below
Researched bygemini-3.8-flash-medium
Valuation Nov 6, 2026 · Price as of Nov 16, 2026How we got here

What does Mckesson do?

McKesson distributes pharmaceuticals, medical-surgical supplies, and laboratory equipment while providing technology and logistics services to pharmacies, healthcare providers, and hospitals.

It brought in $418.8B of sales in the 12 months to Sep 2026.

iKnowMed oncology EHR clinical decision supportImage: Ontada
Industry
Industrials
Based in
Irving, Texas
Trades on
NYSE as MCK

Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 1¢ was left as profit after every cost, interest and tax. The biggest cost is making what it sells, 96¢ of every dollar.

  • Making what it sells96¢
  • Sales, marketing and admin2¢
  • Left as profit1¢
Totals of the four quarters to Sep 2026, from the company's own filings. The split by product is from the latest fiscal year.

Who pays Mckesson, and for what?

McKesson distributes medicines and medical supplies and provides services and technology to pharmacies, healthcare providers, and drug companies. It earns revenue from product distribution and from services such as oncology practice support, medication access technology, and logistics.

Its customers include pharmacies, hospitals, clinics, other healthcare providers, pharmaceutical companies, payors, and government entities.

  • North American Pharmaceutical

    84%

    Distributes medicines and related products in the U.S. and Canada, and provides pharmacy and healthcare services.

  • Oncology & Multispecialty

    12%

    Provides specialty drug distribution, oncology and other specialty practice support, infusion services, research, and related technology.

    iKnowMed oncology EHR clinical decision supportImage: Ontada
  • Medical-Surgical Solutions

    3%

    Distributes medical and laboratory supplies and provides logistics and related services to U.S. providers, mainly outside acute-care hospitals.

  • Prescription Technology Solutions

    1%

    Provides technology and services connecting patients, pharmacies, providers, health plans, and drug companies to support medication access and affordability.

  • Other

    0%

    Includes the former Norwegian operations, which McKesson sold during fiscal 2026.

Share of the latest fiscal year's sales, as the company reports it.

Where its work physically happens, beyond headquarters:

  • Jeffersonville pharmaceutical distribution center — Jeffersonville, United States. This automated distribution center supports pharmaceutical order fulfillment in McKesson’s largest revenue segment.
  • Clermont specialty distribution center — Shepherdsville, United States. Its automated operations fulfill plasma, biologics, and other specialty-drug orders, supporting capacity in a growing product category.
  • CoverMyMeds Columbus hub — Columbus, United States. The hub houses CoverMyMeds teams developing medication access and affordability technology for McKesson’s Prescription Technology Solutions business.
  • McKesson Canada head office — Saint-Laurent, Canada. This office is McKesson Canada’s principal business hub for its Canadian operations.
  • McKesson Medical-Surgical Richmond office — Richmond, United States. The office supports the Medical-Surgical Solutions business, which reported $11.5 billion in fiscal 2026 revenue and is being prepared for separation.
See them on the globe

McKesson Corporation 2026 Form 10-K

How is the business doing?

Sales grew from $238.2B in 2021 to $403.4B in 2026, about 11% a year.

Running the business leaves about 2¢ of each sales dollar as operating profit, up from 2¢ in 2021.

After paying for its upkeep and new investment, it had $7.1B of cash to spare in the 12 months to Sep 2026.

Sales$403.4B
20172026
Operating margin2%
20172026
Free cash flow$5.7B
20172026
Each bar is one fiscal year (2017–2026), summed from four published quarters; the latest is highlighted.

What does management say it's aiming for?

McKesson says its mission is to improve care in every setting, one product, one partner, and one patient at a time.

“To improve care in every setting — one product, one partner, one patient at a time”

McKesson Code of Conduct

What management says it is working on now:

Adjusted earnings per diluted share, Fiscal 2027
$44.20 to $45.00
McKesson Reports Fiscal 2027 First Quarter Results
Adjusted earnings per diluted share growth, Long term
13% to 16%
McKesson Reports Fiscal 2026 Fourth Quarter and Full Year Results
Goals in management's own numbers. A target is a promise, not a result.

What's changing right now?

Growth is holding steady. In Q2 2027 it sold 8% more than a year earlier. The year before, quarters averaged 9%.

Its operating margin is about where it was a year ago, 1¢ per sales dollar.

Since Oct 2026 the share price has risen 13%, from $981.28 to $1,105.04.

Bull $1,684.78Base $1,149.07Bear $764.42Oct 30Nov 16 · $1,105.04
Daily closing prices we have recorded, set against our bear-to-bull range. Our price records start October 30, 2026.

Recently

Coming up

Our own estimate moved too: the base case went from $766.23 to $1,149.07 a share between our last two valuations.

What could go wrong?

No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.

  1. Customer concentration

    The ten largest customers, including purchasing groups, accounted for about 73% of fiscal 2026 revenue. CVS alone accounted for about 24%, so a major change in a large customer relationship could affect sales.

    From the company's own filingsWould hit how fast sales growMcKesson Corporation 2026 Form 10-K

  2. Healthcare policy and regulation

    Changes to drug pricing, public healthcare funding, and rules for pharmacy and drug distribution could change customer demand, operating costs, and the economics of distribution.

    From the company's own filingsWould hit how much of each sale it keepsMcKesson Corporation 2026 Form 10-K

  3. Legal claims involving controlled substances

    McKesson faces opioid-related lawsuits and court orders governing controlled-substance distribution. Outcomes could require payments or changes to operations and may take years to resolve.

    From the company's own filingsWould hit how much of each sale it keepsMcKesson Corporation 2026 Form 10-K

  4. Planned Medical-Surgical separation

    The separation may be delayed, occur on different terms, or not happen. McKesson also says the process could disrupt operations or cost more than expected.

    From the company's own filingsWould hit how fast sales growMcKesson Corporation 2026 Form 10-K

  5. Cybersecurity and system disruptions

    An attack or technology outage affecting McKesson or a service provider could expose sensitive information, interrupt deliveries or services, and lead to lost customers, legal action, or added costs.

    From the company's own filingsWould hit how much of each sale it keepsMcKesson Corporation 2026 Form 10-K

  6. Strong competition

    McKesson competes with large distributors and many regional and specialist providers. Customers may also build their own supply-management services, putting pressure on prices and service costs.

    From the company's own filingsWould hit how much of each sale it keepsMcKesson Corporation 2026 Form 10-K

  7. FY2025 and FY2026 exhibited higher growth of 16.22% and 12.36%, suggesting the potential for faster top-line compounding if GLP-1 indications broaden.

    From our researchWould hit how fast sales growMcKesson Historical Financial Statements

  8. Strategic acquisitions in provider practice management and oncology clinics intermittently demand incremental cash investment.

    From our researchWould hit how much it has to reinvestMcKesson Form 10-K Note 3 Business Combinations

Is it a good business?

From 2017 to 2026 it earned between -478% and 2,186% on the capital invested in it, a median of 24%. Its cost of capital in the latest valuation is 6.8%; returns were above it in 4 of the 7 years.

From 2017 to 2020 it earned between 0% and 46% on its shareholders' equity, a median of 9%.

Over 10 years its operating margin ranged from 2¢ to 4¢ per sales dollar, a median of 1¢. Gross margin ran from 4¢ to 6¢.

derived computed from the filingsassumption cost of capital from the latest valuation
Return on invested capital1,319%
20172026

Cost of capital 6.8%

Return on invested capital is operating profit after tax (at the median effective rate, 20%) over debt plus equity less cash at each fiscal year end. Return on equity is net income over equity. Both are computed from published quarters.

It bought back shares: the count fell 6.2% in a year, so each remaining share owns a slightly bigger slice.

It owes $2.7B more than it holds in cash, about 0.4 years of operating profit.

What might it be worth?

The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .

Today a share costs $1,105.04. Our put its value between $764.42 and $1,684.78, with $1,149.07 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .

Bear case, $764.42

This scenario models a slowdown where growth drops from recent double-digit levels to the low single digits as weight-loss drug demand cools and intense customer bargaining keeps profits slim.

Base case, $1,149.07

This scenario assumes revenue growth settles into the mid-single digits near recent quarterly trends, while profits hold steady as high-margin cancer care services balance high-volume drug deliveries.

Bull case, $1,684.78

This scenario envisions robust high-single-digit growth sustained by expanded uses for weight-loss medications, wider cancer care clinic partnerships, and expanding software profit margins.

Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.

Why the gap?

The price and our value are close.Margin of safety: 4%

For Mckesson to be worth today's $1,105.04, sales would need to grow about 5.2% a year. We assume 6.0%. Over the last 5 years, sales grew 10.8% a year.

−2.5%0%+2.5%+5%+7.5%+10%+12.5%Price needs 5.2%We assume 6.0%Past 5 yrs 10.8%

Or, if sales grow 6.0% as we assume, the price works with a profit margin of 1.5% (we assume 1.6%).

Keep in mind: a gap this small is normal. A small change in almost any assumption would close it.

Do you think sales can grow 5.2% a year?

Try your own numbers

We're moderately sure of this range: it scores 73 out of 100 on our checks. The weakest point is terminal-value dependency.

Test the assumptions

Our base value of $1,149.07 rests on three assumptions. Change any of them to see how the value per share responds.

  • Revenue growth, 5-year average6.0%
  • Operating margin1.6%
  • Long-term growth rate2.8%

This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.

Base estimate

$1,149.07 4.0%

Build